Yifang Biotechnology (688382.SH): The results of the D-2570 treatment for psoriasis II clinical trial will be released at the 2025 annual meeting of the American Academy of Dermatology.

In an announcement, Yifang Biotechnology Co., Ltd. (688382.SH) disclosed that the Phase II clinical trial results of the company's independently developed TYK2 inhibitor D-2570 for the treatment of moderate to severe plaque psoriasis were presented orally in the latest breakthrough research abstract section at the 2025 American Academy of Dermatology (AAD) Annual Meeting. The announcement stated that the Phase II clinical trial data showed that the efficacy of D-2570 in treating patients with severe psoriasis was significantly better than placebo and also superior to similar TYK2 inhibitors currently on the market. In terms of effectiveness, it can also be compared to monoclonal antibody biologics (such as anti-IL-17A, anti-IL-23 antibodies). Overall tolerability was good, and it is expected to provide a new treatment option for patients with autoimmune diseases, including psoriasis, in the future.